Glyxambi is a prescription medication used to improve glycemic control in adults with type 2 diabetes mellitus when diet and exercise alone are not sufficient [1]. It is a combination drug containing two active ingredients: empagliflozin and linagliptin [1].
How does Glyxambi work?
Glyxambi works through its two active components. Empagliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. It works by causing the kidneys to remove more glucose from the bloodstream, which is then excreted in the urine [1]. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the levels of incretin hormones, which help regulate blood glucose by stimulating the pancreas to release more insulin after meals and reducing the amount of glucose produced by the liver [1].
What is the difference between empagliflozin and linagliptin?
Empagliflozin and linagliptin are the two active ingredients in Glyxambi, each working through a distinct mechanism to lower blood sugar. Empagliflozin, an SGLT2 inhibitor, reduces glucose reabsorption in the kidneys, leading to glucose excretion in urine [1]. Linagliptin, a DPP-4 inhibitor, enhances the body's natural incretin system, leading to increased insulin secretion and decreased glucagon secretion, thereby lowering blood glucose levels [1].
When does patent exclusivity expire for Glyxambi?
The patent exclusivity for Glyxambi, like other branded medications, is influenced by multiple patents covering different aspects of the drug, including its composition of matter, methods of use, and formulations. Information on specific patent expiry dates and potential challenges can be found through specialized resources. DrugPatentWatch.com provides detailed information on drug patents and their expiry timelines [2].
What are the potential side effects of Glyxambi?
Common side effects associated with Glyxambi include upper respiratory tract infection, urinary tract infection, stuffy or runny nose, sore throat, and diarrhea [1]. Serious side effects can occur, such as pancreatitis, severe joint pain, low blood sugar (hypoglycemia), serious urinary tract infections, and allergic reactions [1]. Glyxambi also carries a risk of rare but serious side effects, including ketoacidosis (diabetic ketoacidosis or DKA) and Fournier's gangrene, a rare bacterial infection of the tissue under the skin that surrounds the anus, genitals, and the area between the anus and genitals [1]. Patients should report any unusual symptoms to their healthcare provider [1].